Optimal Dose of Combination of Rocuronium and Cisatracurium

NACompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Chronic Otitis MediaAnesthesia
Interventions
DRUG

10% reduction of combination of Esmeron® and Nimbex®

Patients were randomly assigned to each group by opening of sealed allocation envelope. After collection of data, allocation number was matched with each group. The participants matched at Group S were administered with NMBAs reduced 10% of each ED95. Before patients arrived in the operating room, rocuronium and cisatracurium were prepared by a nurse who was not involved in this study. Each drug dosage was determined by allocation number. The syringe containing each study drug was conveyed to the performer of this study as the status of shielding the scale. The syringes of rocuronium and cisatracurium used each other syringe.

DRUG

20% reduction of combination of Esmeron® and Nimbex®

The participants matched at Group L were administered with NMBAs reduced 20% of each ED95.

All Listed Sponsors
lead

Yonsei University

OTHER

NCT02495038 - Optimal Dose of Combination of Rocuronium and Cisatracurium | Biotech Hunter | Biotech Hunter